SecurityBNPZY / BNP Paribas (F1058Q238)
Institutional Owners2
Institutional Shares108,363
Institutional Value$ 8,022,000 USD

Institutional Stock Ownership and Shareholders()

BNP Paribas (OTC:BNPZY) has 2 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 108,363 shares. Largest shareholders include Cullen Capital Management, LLC, and Schafer Cullen Capital Management Inc.
BNP Paribas (OTC:BNPZY) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Prev Value
Current Value
2018-05-14 13F-HR Schafer Cullen Capital Management Inc 38,298 34,153 -10.82 2,863 2,528 -11.70
2018-05-14 13F-HR Cullen Capital Management, LLC 68,640 74,210 8.11 5,131 5,494 7.07

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Dollar in ‘Dangerous Territory’ After Trump Blasts China, EU on FX - Bloomberg

2018-07-20 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


2018-07-20 reuters
July 20 (Reuters) - The following financial services industry appointments were announced on Friday. To inform us of other job changes, email [email protected] (2-0)

4 Chinese Stocks at Risk From China's Currency Crash | InvestorPlace

2018-07-20 investorplace
U.S. equities rolled over on Thursday. Investors are worried about the fallout from a deepening slide in China’s currency. Foreign exchange markets are rapidly pricing in further trouble for Chinese currency — and Chinese stocks — as President Trump steps up his trade rhetoric. Already, $50 billion in tariffs against Chinese imports are coming in. Another $200 billion are on the way. (13-1)

MOVES-BNP Paribas Asset Management hires sustainability head

2018-07-20 reuters
(Reuters) - BNP Paribas Asset Management, the investment management arm of BNP Paribas SA (BNPP.PA), said it had appointed Jane Ambachtsheer as global head of sustainability, effective Aug. 27.

‘This Is Not a Passing Fad’: CFA Exam Adds Crypto, Blockchain Topics - Bloomberg

2018-07-16 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (5-0)

CUSIP: F1058Q238